David Goldenberg an Insider in Immunomedics, Inc. (IMMU) Unloaded 117,729 Shares of the Company; Paradigm Financial Advisors Has Upped Qualcomm (QCOM) Position By $385,356

Paradigm Financial Advisors Llc increased Qualcomm Inc (QCOM) stake by 10.08% reported in 2017Q3 SEC filing. Paradigm Financial Advisors Llc acquired 7,556 shares as Qualcomm Inc (QCOM)’s stock rose 2.14%. The Paradigm Financial Advisors Llc holds 82,532 shares with $4.28 million value, up from 74,976 last quarter. Qualcomm Inc now has $92.98B valuation. The stock decreased 0.35% or $0.22 during the last trading session, reaching $62.81. About 15.80M shares traded or 39.56% up from the average. QUALCOMM Incorporated (NASDAQ:QCOM) has risen 9.31% since March 13, 2017 and is uptrending. It has underperformed by 7.39% the S&P500.

Because of the sell David Goldenberg made he is in the insider trades focus today. The director of Immunomedics Inc and an insider, unloaded 117,729 shares worth $2,049,389 US Dollars. The average price was $17.4 per share. David Goldenberg currently possess 7.39 million shares or 4.46% of Immunomedics Inc’s market cap.

Since September 27, 2017, it had 0 insider purchases, and 5 sales for $2.98 million activity. The insider ROGERS ALEXANDER H sold $48,627. 43,000 shares were sold by GROB MATTHEW S, worth $2.81M on Tuesday, January 9.

Among 36 analysts covering Qualcomm Inc. (NASDAQ:QCOM), 16 have Buy rating, 1 Sell and 19 Hold. Therefore 44% are positive. Qualcomm Inc. has $315.0 highest and $47 lowest target. $75.54’s average target is 20.27% above currents $62.81 stock price. Qualcomm Inc. had 134 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Hold” rating by Stifel Nicolaus given on Wednesday, March 7. Northland Capital maintained the stock with “Hold” rating in Tuesday, August 1 report. RBC Capital Markets maintained QUALCOMM Incorporated (NASDAQ:QCOM) rating on Friday, September 8. RBC Capital Markets has “Hold” rating and $55.0 target. The rating was downgraded by Evercore to “Hold” on Friday, July 1. UBS maintained the shares of QCOM in report on Monday, November 6 with “Buy” rating. The company was maintained on Thursday, August 24 by Stifel Nicolaus. The company was maintained on Thursday, January 26 by Stifel Nicolaus. On Monday, November 6 the stock rating was downgraded by Standpoint Research to “Hold”. The company was downgraded on Monday, January 23 by CLSA. Cowen & Co maintained the shares of QCOM in report on Thursday, July 21 with “Outperform” rating.

Investors sentiment decreased to 0.83 in 2017 Q3. Its down 0.02, from 0.85 in 2017Q2. It dived, as 83 investors sold QCOM shares while 490 reduced holdings. 89 funds opened positions while 397 raised stakes. 1.10 billion shares or 0.88% less from 1.11 billion shares in 2017Q2 were reported. 50,320 are held by Timber Creek Capital Management Ltd Liability Com. Old Dominion Cap holds 0.57% or 10,721 shares. Sns Fincl Gp Ltd Company reported 37,473 shares or 0.5% of all its holdings. Ing Groep Nv reported 62,651 shares. Moreover, Cibc Asset Management Incorporated has 0.06% invested in QUALCOMM Incorporated (NASDAQ:QCOM). Moreover, Pub Employees Retirement Association Of Colorado has 0.1% invested in QUALCOMM Incorporated (NASDAQ:QCOM) for 262,592 shares. Mark Sheptoff Planning Limited Com has 0.01% invested in QUALCOMM Incorporated (NASDAQ:QCOM). Marble Harbor Investment Counsel Ltd Liability Co has invested 0.13% of its portfolio in QUALCOMM Incorporated (NASDAQ:QCOM). Greatmark Investment Partners accumulated 2.5% or 126,139 shares. Lombard Odier Asset Mngmt (Europe) Ltd, United Kingdom-based fund reported 16,866 shares. Kelly Lawrence W Inc Ca stated it has 0.21% in QUALCOMM Incorporated (NASDAQ:QCOM). 248,611 are owned by Manning & Napier Advsrs Ltd Llc. Invest Mngmt Of Virginia Ltd Liability holds 1.12% or 91,602 shares in its portfolio. Botty Limited Liability Corp has invested 0.2% in QUALCOMM Incorporated (NASDAQ:QCOM). Schwab Charles Investment Mgmt invested in 0.34% or 7.50M shares.

Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics has $16 highest and $1.50 lowest target. $15.50’s average target is -10.35% below currents $17.29 stock price. Immunomedics had 15 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Immunomedics, Inc. (NASDAQ:IMMU) earned “Market Perform” rating by Wells Fargo on Friday, December 4. Jefferies maintained Immunomedics, Inc. (NASDAQ:IMMU) on Friday, June 9 with “Buy” rating. The firm has “Buy” rating given on Wednesday, December 6 by Jefferies. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Market Perform” rating given on Tuesday, June 21 by Wells Fargo. As per Wednesday, July 29, the company rating was downgraded by Jefferies. The firm has “Hold” rating by Jefferies given on Tuesday, March 15. As per Wednesday, December 6, the company rating was maintained by Cowen & Co. The firm has “Buy” rating given on Tuesday, September 19 by Jefferies. The company was reinitiated on Thursday, October 6 by Jefferies. Jefferies upgraded the stock to “Buy” rating in Friday, May 6 report.

The stock decreased 0.06% or $0.01 during the last trading session, reaching $17.29. About 1.78M shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 76.26% since March 13, 2017 and is uptrending. It has outperformed by 59.56% the S&P500.

Analysts await Immunomedics, Inc. (NASDAQ:IMMU) to report earnings on May, 9. They expect $-0.13 earnings per share, up 40.91% or $0.09 from last year’s $-0.22 per share. After $-0.19 actual earnings per share reported by Immunomedics, Inc. for the previous quarter, Wall Street now forecasts -31.58% EPS growth.

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company has market cap of $2.87 billion. The firm engages in developing antibody-drug conjugate products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It currently has negative earnings. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody.

Investors sentiment decreased to 1.07 in 2017 Q3. Its down 0.58, from 1.65 in 2017Q2. It fall, as 16 investors sold Immunomedics, Inc. shares while 36 reduced holdings. 38 funds opened positions while 48 raised stakes. 111.69 million shares or 33.14% more from 83.89 million shares in 2017Q2 were reported. Ameritas Partners holds 0% or 8,214 shares in its portfolio. State Common Retirement Fund reported 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Bancshares Of America De owns 66,732 shares. Morgan Stanley stated it has 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Adage Cap Prtnrs Group Inc holds 0.01% or 161,000 shares in its portfolio. Venbio Select Advisor Ltd Co, a California-based fund reported 14.74M shares. Aqr Management Ltd Company holds 0% or 95,265 shares. Creative Planning owns 1.87 million shares for 0.12% of their portfolio. Pnc Fincl Grp Inc Incorporated accumulated 1,721 shares or 0% of the stock. Jane Street Group Inc Lc, New York-based fund reported 22,164 shares. Deutsche Natl Bank Ag has 1.39 million shares. 683 Mngmt Limited Liability stated it has 0.33% in Immunomedics, Inc. (NASDAQ:IMMU). Moreover, Quantbot Technologies L P has 0.01% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 4,754 shares. Ameriprise Financial stated it has 0% in Immunomedics, Inc. (NASDAQ:IMMU). Tiaa Cref Inv Mgmt Ltd holds 0% in Immunomedics, Inc. (NASDAQ:IMMU) or 272,375 shares.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: